clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Stieler Stewart AL et al. Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals. 2017 Equine Vet. J. pmid:28238211
Iwayama K et al. Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. 2017 BMC Pharmacol Toxicol pmid:28235416
Komiya K et al. Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. 2017 Respir. Res. pmid:28219384
Sakurai K et al. Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 World J. Gastroenterol. pmid:28216974
Awan S et al. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. 2017 Lung Cancer pmid:28213005
Su J et al. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. 2017 Medicine (Baltimore) pmid:28207505
Branquinho D et al. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? 2017 BMC Gastroenterol pmid:28202013
Inukai K et al. Effect of gel formation on the dissolution behavior of clarithromycin tablets. 2017 Int J Pharm pmid:28196716
Miftahussurur M et al. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. 2017 Am. J. Trop. Med. Hyg. pmid:28193745
Zhang Z et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. 2017 Int. J. Antimicrob. Agents pmid:28188830
Larsen EL et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. 2017 Br J Clin Pharmacol pmid:28185274
Ivanová L et al. Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. 2017 Environ. Res. pmid:28183039
Kristin F et al. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. 2017 Eur J Pharm Sci pmid:28179133
Naik S and Ruck R In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. 1989 Antimicrob. Agents Chemother. pmid:2817858
Chen D et al. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. 2017 Antimicrob. Agents Chemother. pmid:28167563
Giguère S Treatment of Infections Caused by Rhodococcus equi. 2017 Vet. Clin. North Am. Equine Pract. pmid:28161038
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Olesen JS et al. Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy. 2017 BMJ Case Rep pmid:28137898
Berni E et al. Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. 2017 BMJ Open pmid:28115334
Chang JY et al. Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication. 2017 BMC Gastroenterol pmid:28109257
Sasaoka Y et al. Neonatal apnea with Chlamydia pneumoniae infection. 2017 Pediatr Int pmid:28102626
Ono S et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. 2017 Helicobacter pmid:28098408
Lapa GB et al. Two approaches to the use of benzo[c][1,2]oxaboroles as active fragments for synthetic transformation of clarithromycin. 2017 J Enzyme Inhib Med Chem pmid:28097898
Chen PY et al. Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28074519
Zamani M et al. Letter: levofloxacin resistance - a challenge for the treatment of Helicobacter pylori infection. 2017 Aliment. Pharmacol. Ther. pmid:28074507
Chey WD et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. 2017 Am. J. Gastroenterol. pmid:28071659
Fernández Martos R et al. Acute psychotic episode secondary to Helicobacter pylori eradication treatment. 2017 Rev Esp Enferm Dig pmid:28071063
Lin CM et al. Is ionizing radiation a risk factor to diffuse panbronchiolitis? 2017 QJM pmid:28069906
Takeuchi S et al. Hypotension induced by the concomitant use of a calcium-channel blocker and clarithromycin. 2017 BMJ Case Rep pmid:28069789
Alenezi A et al. Controlled release of clarithromycin from PLGA microspheres enhances bone regeneration in rabbit calvaria defects. 2018 J. Biomed. Mater. Res. Part B Appl. Biomater. pmid:28067984
Tsujimae M et al. A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori. 2016 Digestion pmid:28030862
Radzikowska E et al. Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia. Adv Clin Exp Med pmid:28028949
Zhang X and Hu C Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. 2017 J Pharm Biomed Anal pmid:28024686
Stjepanovic MI et al. Pulmonary and Vertebral Mycobacterium avium Disease in a HIV-negative 71-year-old Man - A Case Report. 2016 Infez Med pmid:28011973
Park J et al. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. 2017 Clin. Infect. Dis. pmid:28011609
Koh WJ et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. 2017 Clin. Infect. Dis. pmid:28011608
Çekin AH et al. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. 2017 Turk J Gastroenterol pmid:28007678
Seyama S et al. Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). 2017 J. Antimicrob. Chemother. pmid:27999037
Yamamoto S et al. Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-κB-mediated cytokine production. 2017 Biochem. Biophys. Res. Commun. pmid:27998764
Chen CH et al. Mycobacterium abscessus complex bacteremia due to prostatitis after prostate biopsy. 2016 Indian J Tuberc pmid:27998503
Santos MA et al. Nothing to (S)cough at: Pulmonary Mycobacterium avium Complex Infection. 2017 Am. J. Med. pmid:27984010
Ramzy I et al. GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS. 2016 Rev. Inst. Med. Trop. Sao Paulo pmid:27982354
Hirasawa K et al. Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines. 2016 PLoS ONE pmid:27977675
Jenkins H et al. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. 2017 Clin Drug Investig pmid:27928738
Gbinigie II and Lasserson D Clarithromycin-induced akathisia: a class effect of macrolides? 2016 BMJ Case Rep pmid:27927708
Miftahussurur M et al. Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. 2016 PLoS ONE pmid:27906990
Gouin-Thibault I et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. 2017 J. Thromb. Haemost. pmid:27893182
Sun W et al. Synergistic drug combination effectively blocks Ebola virus infection. 2017 Antiviral Res. pmid:27890675
Gisbert JP Helicobacter pylori-related diseases. 2016 Gastroenterol Hepatol pmid:27888863
Hung IFN et al. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. 2017 Chest pmid:27884765
Velu PP et al. Pulmonary Mycobacterium marinum infection: 'fish tank granuloma' of the lung. 2016 Scott Med J pmid:27872397
Noh HM et al. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice. 2016 Korean J Gastroenterol pmid:27871162
Aguilera-Correa JJ et al. Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. 2017 Diagn. Microbiol. Infect. Dis. pmid:27863951
Katayama Y et al. Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. 2017 Life Sci. pmid:27825902
Moj D et al. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. 2017 AAPS J pmid:27822600
Fan W et al. An unusual case of folliculitis spinulosa decalvans. 2016 Cutis pmid:27814407
Miftahussurur M et al. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. 2016 BMC Microbiol. pmid:27809767
Kajihara Y et al. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. 2017 Scand. J. Gastroenterol. pmid:27806639
Shaulov A et al. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. 2017 Am. J. Hematol. pmid:27804150
Mougari F et al. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. 2017 Antimicrob. Agents Chemother. pmid:27799212
Morimoto K et al. A Laboratory-based Analysis of Nontuberculous Mycobacterial Lung Disease in Japan from 2012 to 2013. 2017 Ann Am Thorac Soc pmid:27788025
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Baluch A et al. Successful management of Mycobacterium haemophilum lower extremity cutaneous infection in a matched-unrelated donor stem cell transplant recipient. 2017 Transpl Infect Dis pmid:27775824
Liou JM et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. 2016 Lancet pmid:27769562
Chauffour A et al. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. 2016 PLoS Negl Trop Dis pmid:27755552
Kekilli M et al. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori. Saudi J Gastroenterol pmid:27748322
Ikeda H et al. Severe Disseminated Mycobacterium avium Infection in a Patient with a Positive Serum Autoantibody to Interferon-γ. Intern. Med. pmid:27746449
Bichler EK et al. Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling. 2017 J. Neurophysiol. pmid:27733592
Kasai C et al. Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. 2016 BMC Gastroenterol pmid:27716077
Malfertheiner P et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. 2017 Gut pmid:27707777
Mougari F et al. Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. 2016 Expert Rev Anti Infect Ther pmid:27690688
Noda H et al. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori. 2016 J Gastrointestin Liver Dis pmid:27689190
Giorgio F et al. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. 2016 Scand. J. Gastroenterol. pmid:27687850
Chang KH et al. Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. 2017 J. Matern. Fetal. Neonatal. Med. pmid:27687157
Sanches BS et al. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. 2016 World J. Gastroenterol. pmid:27672279
Yeo YH et al. First-line eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. 2018 Gut pmid:27670375
Li M et al. Inducible Expression of both ermB and ermT Conferred High Macrolide Resistance in Streptococcus gallolyticus subsp. pasteurianus Isolates in China. 2016 Int J Mol Sci pmid:27669217
Narita M et al. Antimicrobial Susceptibility of Microorganisms Isolated from Periapical Periodontitis Lesions. 2016 Bull. Tokyo Dent. Coll. pmid:27665691
Abuhammour A et al. Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients. 2016 Arab J Gastroenterol pmid:27665525
Matsumoto H et al. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance. 2016 Dig. Dis. Sci. pmid:27659671
Varma MV et al. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. 2017 Clin. Pharmacol. Ther. pmid:27648490
Huet D et al. [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. 2017 Rev Mal Respir pmid:27639948
El Haj C et al. The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? 2017 Med. Microbiol. Immunol. pmid:27639707
Ohe M et al. A case of lupus nephritis treated with clarithromycin, tacrolimus, and glucocorticoids. 2016 Kaohsiung J. Med. Sci. pmid:27638410
Iwańczak BM et al. Assessment of Sequential and Standard Triple Therapy in Treatment of Helicobacter pylori Infection in Children Dependent on Bacteria Sensitivity to Antibiotics. Adv Clin Exp Med pmid:27629844
Zycinska K et al. Antibiotic Treatment of Hospitalized Patients with Pneumonia Complicated by Clostridium Difficile Infection. 2016 Adv. Exp. Med. Biol. pmid:27620311
Tsugawa K et al. Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells. 2017 Clin. Exp. Nephrol. pmid:27614743
Hajiaghamohammadi AA et al. To evaluate of the effect of adding licorice to the standard treatment regimen of Helicobacter pylori. Braz J Infect Dis pmid:27614124
Phaw NA and Tsai HH Eosinophilic gastroenteritis: a challenge to diagnose and treat. 2016 BMJ Case Rep pmid:27613263
Plate A [Not Available]. 2016 Praxis (Bern 1994) pmid:27606919
Donzelli A Helicobacter pylori Eradication? 2016 Gastroenterology pmid:27590693
Hirata Y et al. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen. 2016 Int. J. Infect. Dis. pmid:27590563
Huh CW et al. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. 2016 PLoS ONE pmid:27588679
Watanabe M et al. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. 2016 Int J Pharm pmid:27553780
Vlachogianni P et al. Mycobacterium avium Auricular Infection in an Apparent Immunocompetent Patient: A Case Report. Folia Med (Plovdiv) pmid:27552790
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Couture G et al. [Second case of serum sickness-like reaction to claritrhomycin]. 2016 Presse Med pmid:27542759
Bugli F et al. In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. 2016 Biotechnol. Prog. pmid:27535356
Shichijo S et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice. 2016 J Dig Dis pmid:27534444
Gehlot V et al. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. 2016 J Glob Antimicrob Resist pmid:27530837